Avacta to present promising new data from Affimer and pre|CISIONTM platform assets at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Seite 2

Session:                                             Poster Session A                             
Session date and time:                  Thursday, October 12 | 12:30 pm-4:00 pm
Session location:                             Level 2, Exhibit Hall D

Dr Fiona McLaughlin, Chief Scientific Officer of Avacta commented:
“We look forward to presenting the promising new data from Avacta’s Therapeutics platform assets at this conference. As disclosed in the Company’s announcement on 19 September 2023, our lead asset AVA6000 continues to advance through the clinic at pace. We are simultaneously conducting IND-enabling studies for promising assets derived from the pre|CISION^TM and Affimer platforms. The data to be presented showcases the potential of our two therapeutic platforms to generate further high value clinical assets.

“AVA3996, a FAP-α-activated proteasome inhibitor based on our pre|CISION^TM technology, demonstrates targeted killing of cancer cells in vitro and, by concentrating the active warhead in the tumour, reduces systemic toxicity associated with this class of drug.

“AVA032, our anti-PD-L1 Affimer fused to the pro-inflammatory cytokine interleukin 15 (IL-15) displays encouraging efficacy when tested in multiple models of immunomodulation, stimulating a potent immune response and reversing the immunosuppressive tumour microenvironment.”

Further information regarding the conference can be found on the ACCR’s website here: https://www.aacr.org/meeting/aacr-nci-eortc-international-conference-o ...

The posters will be available to view following the conference here: https://avacta.com/about/scientific-resources/

-Ends-

For further information from Avacta Group plc, please contact:

Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer Michael Vinegrad, Group Communications Director